Clinical-stage immuno-oncology company VCN Biosciences is developing a portfolio of its own uniquely designed therapeutic oncolytic adenoviruses. The company’s experienced team is currently ...

VCN has a low expense ratio of 0.05% but high exposure to cyclical sectors and low exposure to technology, leading to underperformance against the S&P 500. VCN's sector allocation, heavily ...